Сirculating tumour cells: molecular properties and anti-cancer treatment monitoring

Циркулирующие раковые клетки: молекулярная характеристика и мониторинг лечения рака
Abay Baigenzhin 1, Galiya Shaimardanova 2, Nadezhda Popova 3, Bakhit Zhussipova 4, Gulziya Ismailova 5
More Detail
1 General Director of the «National Scientifi c Medical Research Center» JSC
2 Head of the path-morphological department the NSMRC
3 Head of the central research laboratory the NSMRC
4 Head of the Chemotherapy unit, the Oncology clinic Astana
5 Secretary of Academic Council the NSMRC
J CLIN MED KAZ, Volume 4, Issue 30, pp. 9-13.
OPEN ACCESS 3363 Views 2561 Downloads
Download Full Text (PDF)

ABSTRACT

Existence of circulating tumor cells (CTCs) in blood of cancer patients, testifi es about a dissemination of cancer cells to the peripheral blood stream, on the earliest stages of cancer development and very often testifi es to an adverse clinical current, especially it is connected with formation of metastases. Besides, these cells can represent the minimum residual disease and quantitative monitoring of CTCs level in time of anti-cancer treatment provides researchers with valuable information. For today the role of epithelial-to-mesenchymal transit (EMT) and mesenchymal-to-epithelial transit (MET) in formation of various subpopulations CTCs, in expansion of cancer aggressive properties. In this article we want to prove the purpose and problems of our scientifi c research - the cytological molecular analysis of circulating tumour cells have isolated by the size dependent ISET technology (Isolation by size of epithelial tumor cells). To study the cyto-morphological and immunological characteristic, to identify targeted therapy markers and the metastatic response predictors to anti-cancer treatment on viable circulating cancer cells by the RT-PCR method (real-time polymerase chained action). To study of clinical profi t from quantitative, immunological and molecular monitoring of CTCs, for elimination minimum residual disease, by application of individual targeted therapy, on the basis cytological molecular analysis of CTCs.
Keywords: cell, cancer, cyto-immunology, targeted therapy, chemotherapy

CITATION

Baigenzhin A, Shaimardanova G, Popova N, Zhussipova B, Ismailova G. Сirculating tumour cells: molecular properties and anti-cancer treatment monitoring. Journal of Clinical Medicine of Kazakhstan. 2013;4(30):9-13.

REFERENCES

  • Alix-Panabieres C, Muller V, Pantel K. // Current status in human breast cancer micrometastasis. // Curr. Opin. Oncol. 2007;19, 558–563.
  • Alix-Panabieres C, Riethdorf S, Pantel K. // Circulating tumor cells and bone marrow micrometastasis. // Clin. Cancer Res. 2008;14, 5013–5021.
  • Eccles SA, Welch DR. // Metastasis: recent discoveries and novel treatment strategies. // Lancet 2007;369, 1742– 1757.
  • Ge MJ, Shi D, Wu QC, Wang M, Li LB. // Observation of circulating tumour cells in patients with non-small cell lung cancer by real-time fl uorescent quantitative reverse transcriptase-polymerase chain reaction in peroperative period. // J. Cancer Res Clin Oncol. 2006; Apr; 132(4):248-56.
  • Kazuya Yamaguchi, Yukihiro Takagi, Shinichirou Aoki, Manabu Futamura, and Shigetoyo Saji// Signifi cant Detection of Circulating Cancer Cells in the Blood by Reverse Transcriptase–Polymerase Chain Reaction During Colorectal Cancer Resection // Ann Surg. 2000; July; 232(1): 58–65.
  • Maheswaran, S., L.V. Sequist, S. Nagrath, L. Ulkus, B. Brannigan, C.V. Collura, E. Inserra, S. Diederichs, A.J. Iafrate, D.W. Bell, et al . // Detection of mutations in EGFR in circulating lung-cancer cells. // N. Engl. J. Med. 2008. 359:366–377.
  • Nagrath, S., L.V. Sequist, S. Maheswaran, D.W. Bell, D. Irimia, L. Ulkus, M.R. Smith, E.L. Kwak, S. Digumarthy, A. Muzikansky, et al . // Isolation of rare circulating tumour cells in cancer patients by microchip technology. // Nature. 2007.450:1235–1239.
  • Pantel K, Brakenhoff RH, Brandt B. // Detection, clinical relevance and specifi c biological properties of disseminating tumour cells. // Nat. Rev. Cancer 2008; 8, 329–340.
  • SooYeun Park, Gyu-Seog Choi, Jun Seok Park, Hye Jin Kim, Jong-PilRyuk, and Whon-Ho Choi // Infl uence of surgical manipulation and surgical modality on the molecular detection of circulating tumor cells from colorectal cancer // J Korean Surg Soc. 2012 June; 82(6): 356–364.
  • Paterlini-Brechot P, Benali NL. // Circulating tumor cells (CTC) detection: clinical impact and future directions. // Cancer Lett. 2007; 253, 180–204.
  • Stott, S.L., C.H. Hsu, D.I. Tsukrov, M. Yu, D.T. Miyamoto, B.A. Waltman, S.M. Rothenberg, A.M. Shah, M.E. Smas, G.K. Korir, et al. // Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. // Proc. Natl. Acad. Sci. USA.2010b. 107:18392–18397.
  • Vogel I, Kalthoff H. // Disseminated tumour cells. Their detection and signifi cance for prognosis of gastrointestinal and pancreatic carcinomas. // Virchows Arch. 2001; 439, 109–117.
  • V.J.Hofman, M.I.Ilie, Ch.Bonnetaud, E.Selva, E.Long, Th.Molina, J.M.Vignaud, J.F.Flеjou, S.Lantuejoul, E.Piaton, C.Butori, N.Mourad, M.Poudenx, Ph.Bahadoran, S.Sibon, N.Guevara, J.Santini, N.Vеnissac, J.Mouroux, Ph.Vielh, and P.M.Hofman// Cytopathologic Detection of Circulating Tumor Cells Using the Isolation by Size of Epithelial Tumor Cell Method // Am J Clin Pathol 2011; 135:146-156
  • M. Ilie, E. Long, C. Butori, V. Hofman, C. Coelle, V. Mauro, K. Zahaf, C.H. Marquette, J. Mouroux, P. PaterliniBréchot & P. Hofman. ALK-gene rearrangement: a comparative analysis on circulating tumour cells and tumour tissue from patients with lung adenocarcinoma Annals of Oncology 0: 1–7, 2012.
  • National Medical Policy // Circulating Tumor Cells // Policy Number: NMP 513 // Effective Date: June 2012.
  • Songdong Meng, Debasish Tripathy, Eugene P. Frenkel, et al. Circulating Tumor Cells in Patients with Breast Cancer Dormancy. American Association for Cancer Research, Vol. 10, 8152–8162, December 15, 2004.
  • National Medical Policy // Molecular Tumor Markers for Non-Small Cell Lung Cancer (NSCLC) // Policy Number: NMP206 // Effective Date: November 2010 // Update: September 2011.
  • S. Aebi, T. Davidson, G. Gruber & F. Cardoso On behalf of the ESMO Guidelines Working Group clinical practice uidelines // Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Annals of Oncology 22 (Supplement 6): vi12–vi24, 2011.
  • E. Van Cutsem, B. Nordlinger & A. Cervantes On behalf of the ESMO Guidelines Working Group clinical practice guidelines // Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment// Annals of Oncology 21 (Supplement 5): v93–v97, 2010.
  • A. Horwich, C. Parker, C. Bangma & V. Kataja On behalf of the ESMO Guidelines Working Group // Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Annals of Oncology 21 (Supplement 5): v129–v133, 2010.